GSK plans expansion in China despite bribery allegationsBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4744 (Published 25 July 2013) Cite this as: BMJ 2013;347:f4744
- Jane Parry
- 1Hong Kong
In the wake of the bribery scandal engulfing GlaxoSmithKline in China, chief executive officer Andrew Witty has said that the company remains committed to operating there, and may introduce tiered pricing, as it has in other developing regions such as Africa.
At a press conference on 24 July, Witty largely reiterated what had previously been said in public statements from the company regarding the allegations by the Chinese authorities that four of its senior staff in China had been engaged in widespread fraud.1
Witty said, “To …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial